Physician profile
Walter Edwin Watts
NPI 1174784540
$10,479.22
in general payments reported to CMS, 2019-2025
53 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $156 · 2021: $937 · 2022: $4,908 · 2023: $2,092 · 2024: $1,824 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,096 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,095.56 |
| Education | $206.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,216.14 | 2021-2024 | Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray |
| Lilly USA, LLC | $768.95 | 2021-2024 | Retevmo, Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $683.19 | 2020-2025 | Enhertu, Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $651.35 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $567.81 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $406.96 | 2021-2025 | Carvykti, Darzalex, Talvey |
| Eisai INC. | $313.65 | 2021-2024 | |
| Amgen INC. | $273.58 | 2021-2023 | Kyprolis, Vectibix, Nplate |
| Bayer Healthcare Pharmaceuticals INC. | $270.60 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $237.23 | 2021-2024 | Libtayo |
| Genzyme Corporation | $231.05 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.93 | 2022-2025 | Ninlaro, Alunbrig, Iclusig |
| Ipsen Biopharmaceuticals, INC | $221.94 | 2021-2023 | Tazverik |
| Daiichi Sankyo INC. | $209.08 | 2021-2024 | Enhertu, Injectafer |
| Seagen INC. | $181.29 | 2020-2023 | Adcetris, Tukysa |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.